Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADORE: Novel ruxolitinib combinations in myelofibrosis
jRCT2031220109Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-essential thrombocythemia myelofibrosis (PET-MF) and 1 more (14 arms), sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities within the first 2 cycles and Response rate at the end of cycle 6 or cycle 8. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-essential thrombocythemia myelofibrosis (PET-MF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on jRCT2031220109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220109.